News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 on August 13, 2012

BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2012-- Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2012 on Monday, August 13, 2012, and will hold a conference call on Tuesday, August 14, 2012 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information

Date:

  Tuesday, August 14, 2012

Time:

9:00 a.m. eastern time

Toll-Free:

800 561.2718

Toll:

617 614.3525

Pass Code:

62242246

Webcast & Conference Call Slides:

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

 

A replay of the call will be available as a webcast on www.arraybiopharma.com.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.

Source: Array BioPharma Inc.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com